Cat. No. 4666
Chemical Name: 2-Phenylamino-1,4-[4-(pyrrolidinyl)
Biological ActivityPotent inhibitor of L3MBTL3 methyllysine (Kme) reader domain (IC50 = 40 nM; Kd = 120 nM). Displays >100-fold selectivity over a panel of histone methyltransferases, kinases, ion channels and 7-TM receptors. Disrupts subnuclear localization and foci formation of fluorescently-labeled L3MBTL3 in HEK293 cells.
Licensing InformationThis probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the UNC 1215 probe summary on the SGC website.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of UNC 1215 is reviewed on the chemical probes website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
James et al (2013) Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat.Chem.Biol. [Epub ahead of print]. PMID: 23292653.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses UNC 1215 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: UNC 1215, supplier, UNC1215, MBT, L3MBTL3, domain, epigenetics, readers, inhibitors, inhibits, selective, potent, in, vitro, sgc, Tocris Bioscience, MBT Domain Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective inhibitor of cat eye syndrome chromosome region, candidate 2 (CECR2)NI 42
High affinity BRPF inhibitorBI 9564
Potent and selective BRD9 and BRD7 inhibitor; orally activeISOX DUAL
Dual BRD4 and CBP/p300 bromodomain inhibitorISOX INACT
Negative control for PF-CBP1 (Cat. No. 5801)
Tocris has a collaboration with the Structural Genomics Consortium (SGC) to provide the latest high quality epigenetics probes.